Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy

Back to Search
Print
Bookmark Trial

NCT01521884

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
UZ Gasthuisberg
Leuven, , 3000, Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Patients who:

- Are active RA patients (as judged by treating MD)

- Are 18 years of age or older at time of consent

- Are scheduled by their rheumatologist to initiate SC anti-TNF-α therapy + MTX

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Use of biologics (or any experimental drug) in the last 3 months before initiation of SC
anti-TNF-α therapy.


Participation in other clinical or observational trials

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Rheumatoid ArthritisStudy Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis NCT00141830
  1. Largo, Florida
  2. Palm Harbor, Florida
  3. Sarasota, Florida
  4. Boise, Idaho
  5. Kansas City, Kansas
  6. Frederick, Maryland
  7. Albuquerque, New Mexico
  8. Charlotte, North Carolina
  9. Duncansville, Pennsylvania
  10. Austin, Texas
  11. Dallas, Texas
  12. San Antonio, Texas
  13. Spokane, Washington
  14. La Crosse, Wisconsin
  15. Penticton, British Columbia
  16. Newmarket, Ontario
  17. Toronto, Ontario
  18. Montréal, Quebec
  19. Trois-Rivières, Quebec
  20. Saskatoon, Saskatchewan
  21. Quebec,
  22. Budapest,
  23. Békéscsaba,
  24. Veszprém,
  25. Brescia,
  26. Genova,
  27. Pavia,
  28. Roma,
  29. Siena,
  30. Jalisco, Guadalajara
  31. Delegacion Cuahutemoc,
  32. Andalucia,
  33. Castilla la Mancha,
  34. Comunidad Valenciana,
  35. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisStudy Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 NCT01059864
  1. Birmingham, Alabama
  2. Huntsville, Alabama
  3. Gilbert, Arizona
  4. Scottsdale, Arizona
  5. Upland, California
  6. Jacksonville, Florida
  7. Dayton, Ohio
  8. Mayfield Village, Ohio
  9. Greenville, South Carolina
  10. Allen, Texas
  11. Seoul,
  12. Seoul,
  13. Seoul,
  14. Seoul,
  15. Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisEffects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA) NCT01164579
  1. Gilbert, Arizona
  2. Huntington Beach, California
  3. Upland, California
  4. Ormond Beach, Florida
  5. Pinellas Park, Florida
  6. St. Petersburg, Florida
  7. Oklahoma City, Oklahoma
  8. Allen, Texas
  9. Buenos Aires,
  10. Buenos Aires,
  11. Buenos Aires,
  12. Valdivia, Region XIV
  13. Osorno, X Region
  14. Split,
  15. Zagreb,
  16. Hostivice,
  17. Praha 11 - Chodov,
  18. Praha 1,
  19. Praha 1,
  20. Praha 2,
  21. Uherske Hradiste,
  22. Zlin,
  23. Zlin,
  24. Balatonfured,
  25. Budapest,
  26. Budapest,
  27. Debrecen,
  28. Gyor,
  29. Mexico, D. F.
  30. Mexico, D.f.
  31. Mexico, Distrito Federal
  32. Chapultepec,
  33. Chihuahua,
  34. Mexico D.F.,
  35. San Luis Potosi,
  36. Bialystok,
  37. Poznan,
  38. Torun,
  39. San Juan,
  40. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisThree Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks NCT00147498
  1. Upland, California
  2. Clearwater, Florida
  3. Miami, Florida
  4. New Port Richey, Florida
  5. Ocala, Florida
  6. Orlando, Florida
  7. Port Richey, Florida
  8. Tampa, Florida
  9. Dubuque, Iowa
  10. Dubuque, Iowa
  11. Concord, New Hampshire
  12. Plainview, New York
  13. Charlotte, North Carolina
  14. Hickory, North Carolina
  15. Hickory, North Carolina
  16. Dayton, Ohio
  17. Ducansville, Pennsylvania
  18. Johnstown, Pennsylvania
  19. Charleston, South Carolina
  20. Columbia, South Carolina
  21. Nashville, Tennessee
  22. Dallas, Texas
  23. Everett, Washington
  24. Tacoma, Washington
  25. Gent,
  26. Goiânia, GO
  27. Goiânia, GO
  28. Curitiba, PR
  29. São Paulo, SP
  30. São Paulo, SP
  31. Edmonton, Alberta
  32. Victoria, British Columbia
  33. Saint John's, Newfoundland and Labrador
  34. London, Ontario
  35. Toronto, Ontario
  36. Berlin,
  37. Dresden,
  38. Hamburg,
  39. Hildesheim,
  40. Leipzig,
  41. Muenchen,
  42. Neubrandenburg,
  43. Wiesbaden,
  44. Firenze,
  45. Genova,
  46. Pavia,
  47. México, D.f.
  48. Tlalpan Seccion 16, DF
  49. Guadalajara, Jalisco
  50. Aguascalientes,
  51. San Luis Potosí,
  52. Kosice,
  53. Piestany,
  54. Zilina,
  55. L´hospitalet de Llobregat, Barcelona
  56. Santiago de Compostela, La Coruña
  57. Barcelona,
  58. Guadalajara,
  59. Madrid,
  60. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-? Therapy
Official Title Longitudinal Changes In Fatigue And Health Status (aims2) In Ra Patients Treated With Sc Anti-tnf-alpha Therapy
Brief Summary People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.
Detailed Description Observational prospective study Purely descriptive
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population patients seen in a rheumatology practice
Condition Rheumatoid Arthritis
Intervention Other: SC anti-TNF
SC anti-TNF
Study Groups/Cohorts RA Patients treated with SC anti-TNF
Intervention: Other: SC anti-TNF
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: February 3, 2015)		62
Original Estimated Enrollment
 (submitted: January 30, 2012)		75
Actual Study Completion Date February 2014
Actual Primary Completion Date February 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Patients who:

  • Are active RA patients (as judged by treating MD)
  • Are 18 years of age or older at time of consent
  • Are scheduled by their rheumatologist to initiate SC anti-TNF-? therapy + MTX

Exclusion Criteria:

Use of biologics (or any experimental drug) in the last 3 months before initiation of SC anti-TNF-? therapy.

Participation in other clinical or observational trials

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Belgium
Removed Location Countries  
 
Administrative Information
NCT Number NCT01521884
Other Study ID Numbers 0881A1-4748
B1801046 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2015